The US represents the world’s largest biotechnology market, leading with its innovation, extensive R&D, and regular company developments in various spheres of the biotechnology sector. On the back of rising instances of innovations in the information technology, world-class healthcare infrastructure, and active participation by private players, the US biotech industry has grown stupendously in the past few years.
The report, “US Biotech Market Analysis”, covers the Medical Biotechnology, Agricultural Biotechnology, and Industrial Biotechnology segments of the sector. The research finds out which is the largest segment in the biotechnology sector, and why. It also discusses the wider role of the technology.
According to our report, biotech funding has been a major source of growth in the US biotech industry as venture capital and financing by other sources continue to provide the momentum. The structure of financing has been strengthening over the past few years with IPOs, FPOs, public and private sector, and venture funds contributing significantly to the industry developments. Rising focus of companies towards drug development, increasing coverage of various diseases, and significant market potential are some of the prominent factors propelling investments in the recent years.
The report also elaborates the important Bio-clusters prevailing in the US and analyses their growth. It observed that California accounted for the highest growth and attracted maximum funds for research activities. How much employment this cluster generated in the biopharmaceutical sector, has also been covered in the study.
Biotechnology is a priority sector for the government, which has been backing significant developments in the industry. The report identifies key trends in the sector. Of these, bio-similars are found to drive the market positively. It also highlights the competitive landscape in the US biotechnology sector, and lists significant developments of the key players in the segment.
The report finds that the future outlook of the US biotech sector is positive with a substantial amount of investment expected in the research and entrepreneurship development in near future.